The use of ultrasound in endoscopy allows more precise delivery of sclerosant to observed varices. It theoretically allows one to target the vein feeding the varices, obliterate its origin and prevent the redevelopment of future varices at that site. Aims: We aimed to assess the efficacy of endoscopic ultrasound (EUS)-guided sclerotherapy in comparison to conventional sclerotherapy (via gastroscopy) in preventing future gastroesophageal variceal bleeds. Methods: A systematic review was performed using MEDLINE, EMBASE and Cochrane databases from inception to May 2018. The primary outcome was variceal bleed event rate. Secondary outcomes were all-cause gastrointestinal bleed event rate, percentage of patients with successful variceal eradication after first treatment, and adverse event rate. Two independent reviewers extracted data. Mantel-Haenszel random effect model meta-analysis was used whenever methodologically appropriate. Results: Five out of 3,257 identified studies met the inclusion criteria. 2 more studies were excluded due to incomplete data. Studies were performed between 2014 and 2017. EUS-guided sclerotherapy was significantly associated with lower varicealrelated bleeds [RR 0.34 (95% CI 0.14 to 0.82, p = 0.02)], as well as lower all-cause gastrointestinal bleed [RR 0.41 (95% CI 0.26 to 0.64; p<0.0001)]. There was no difference in the percentage of patients with successful variceal obliteration after first treatment [RR 1.05, 95% CI 0.90 to 1.23, (p=0.53)]. There was no statistical heterogeneity in any of the analyses (p= Non-significant, I 2 =0). There was no significant difference in adverse events between the two modalities. Conclusions: EUS-guided sclerotherapy significantly decreases the risk of varicealrelated bleeds and all-cause gastrointestinal bleeds and should be considered when available.
